<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33576234</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1948-7193</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>03</Day></PubDate></JournalIssue><Title>ACS chemical neuroscience</Title><ISOAbbreviation>ACS Chem Neurosci</ISOAbbreviation></Journal><ArticleTitle>Comparison of Two Clinical Upper Motor Neuron Burden Rating Scales in ALS Using Quantitative Brain Imaging.</ArticleTitle><Pagination><StartPage>906</StartPage><EndPage>916</EndPage><MedlinePgn>906-916</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acschemneuro.0c00772</ELocationID><Abstract><AbstractText>Several clinical upper motor neuron burden scales (UMNSs) variably measure brain dysfunction in amyotrophic lateral sclerosis (ALS). Here, we compare relationship of two widely used clinical UMNSs in ALS (Penn and MGH UMNSs) with (a) neuroimaging markers of brain dysfunction and (b) neurological impairment status using the gold-standard functional measure, the revised ALS Functional Rating Scale (ALSFRS-R). MGH UMNS measures hyperreflexia alone, and Penn UMNS measures hyperreflexia, spasticity, and pseudobulbar affect. Twenty-eight ALS participants underwent both Penn and MGH UMNSs, at a matching time-point as a simultaneous [<sup>11</sup>C]PBR28 positron emission tomography (PBR28-PET)/Magnetic Resonance scan and ALSFRS-R. The two UMNSs were compared for localization and strength of association with neuroimaging markers of: (a) neuroinflammation, PBR28-PET and MR Spectroscopy metabolites (myo-inositol and choline) and (b) corticospinal axonal loss, fractional anisotropy (FA), and MR Spectroscopy metabolite (<i>N</i>-acetylaspartate). Among clinical UMN manifestations, segmental hyperreflexia, spasticity, and pseudobulbar affect occurred in 100, 43, and 18% ALS participants, respectively. Pseudobulbar affect did not map to any specific brain regional dysfunction, while hyperreflexia and spasticity subdomains significantly correlated and colocalized neurobiological changes to corticospinal pathways on whole brain voxel-wise analyses. Both UMNS total scores showed significant and similar strength of association with (a) neuroimaging changes (PBR28-PET, FA, MR Spectroscopy metabolites) in primary motor cortices and (b) severity of functional decline (ALSFRS-R). Hyperreflexia is the most frequent clinical UMN manifestation and correlates best with UMN molecular imaging changes in ALS. Among Penn UMNS's subdomains, hyperreflexia carries the weight of association with neuroimaging markers of biological changes in ALS. A clinical UMN scale comprising hyperreflexia items alone is clinically relevant and sufficient to predict the highest yield of molecular neuroimaging abnormalities in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Makary</LastName><ForeName>Meena M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0002-5834-4872</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, A. A. Martinos Center for Biomedical Imaging, Harvard Medical School, Charlestown, Massachusetts 02129, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Systems and Biomedical Engineering Department, Faculty of Engineering, Cairo University, Giza, 12613, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weerasekara</LastName><ForeName>Akila</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, A. A. Martinos Center for Biomedical Imaging, Harvard Medical School, Charlestown, Massachusetts 02129, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodham</LastName><ForeName>Haley</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Sean M Healey &amp; AMG Center for ALS, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hightower</LastName><ForeName>Baileigh G</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, A. A. Martinos Center for Biomedical Imaging, Harvard Medical School, Charlestown, Massachusetts 02129, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Chieh-En J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, A. A. Martinos Center for Biomedical Imaging, Harvard Medical School, Charlestown, Massachusetts 02129, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chew</LastName><ForeName>Sheena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sean M Healey &amp; AMG Center for ALS, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sean M Healey &amp; AMG Center for ALS, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of PM&amp;R, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, Massachusetts 02129, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratai</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, A. A. Martinos Center for Biomedical Imaging, Harvard Medical School, Charlestown, Massachusetts 02129, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Z&#xfc;rcher</LastName><ForeName>Nicole R</ForeName><Initials>NR</Initials><Identifier Source="ORCID">0000-0003-0271-6304</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, A. A. Martinos Center for Biomedical Imaging, Harvard Medical School, Charlestown, Massachusetts 02129, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hooker</LastName><ForeName>Jacob M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-9394-7708</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, A. A. Martinos Center for Biomedical Imaging, Harvard Medical School, Charlestown, Massachusetts 02129, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atassi</LastName><ForeName>Nazem</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Sean M Healey &amp; AMG Center for ALS, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sanofi Genzyme, Cambridge, Massachusetts 02142, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babu</LastName><ForeName>Suma</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sean M Healey &amp; AMG Center for ALS, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>S10 OD023517</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR026666</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 NS083715</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Chem Neurosci</MedlineTA><NlmUniqueID>101525337</NlmUniqueID><ISSNLinking>1948-7193</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">[11C]PBR28</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">positron emission tomography</Keyword><Keyword MajorTopicYN="N">upper motor neuron burden</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>12</Day><Hour>8</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33576234</ArticleId><ArticleId IdType="doi">10.1021/acschemneuro.0c00772</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>